Ratings Neogen Corporation

Equities

NEOG

US6404911066

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
13.26 ^USD	-0.30%		-2.07%	-34.06%

Apr. 30	Neogen® Launches New Molecular Method for Detection of Two Salmonella Serotypes	CI
Apr. 18	Neogen Corporation Forms Genomics Relationship with Performance Food Group	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
NEOGEN CORPORATION	-34.06%	2.87B	C
ABBOTT LABORATORIES	-5.56%	181B	C+
MEDTRONIC PLC	-0.11%	108B	C
BECTON, DICKINSON AND COMPANY	-6.17%	66.12B	A
DEXCOM, INC.	+2.64%	50.65B	B-
CENCORA, INC.	+6.58%	43.11B	B-
HOYA CORPORATION	+4.91%	41.3B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+21.98%	31.6B	B
TERUMO CORPORATION	+14.45%	25.03B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-5.81%	24.16B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes